Issues in Biological Sciences and Pharmaceutical Research
Vol.3(7),pp.63-70, July 2015
Article ID /15/BSPR/015/08 pages
Available online at https://www.journalissues.org/IBSPR/
Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.
Original Research Article
Effect of 2-Methoxyestradiol (2ME) an anti-angiogenic agent on in vivo tumour bearing mouse
Srabantika Mallick1, Goutam Paul2, and Samarendra Nath Banerjee1*
1Department of Zoology, Rammohan College, 102/1 Raja Rammohan Sarani, Kolkata – 700009, India.
2Department of Physiology, The University of Kalyani, Kalyani, Nadia, India.
*Corresponding Author E.mail: samban2kcal(at)yahoo.com
2-Methoxyestradiol (2-ME), once considered an inactive end metabolite of estradiol, has emerged as a very promising agent for cancer treatment. 2 ME was reported to inhibit the proliferation of cells in different tumour cell lines. But it is necessary to investigate the effect of 2ME on in vivo system. So the present study was undertaken to evaluate the efficacy and safety of 2ME on in vivo mouse tumour model considering tumour growth rate with nature of vascular density, mouse survival rate and bone marrow toxicity. Tumour regression in response to different concentrations of 2ME was studied at different time intervals by morphometric analysis of tumor size. A steady decrease in tumour growth was noted after the treatment of 0.1mg ME in tumour bearing mouse which was correlated with the gradual increase of mouse survival or life span. In addition, 0.1mg ME not only induced a strong anti-angiogenic response by a decline in the number of blood vessels in the tumour but also protect bone marrow by inhibition of maximum numbers of affected cell with chromosomal aberrations. So 2-Methoxyestradiol may be applied as a novel therapeutic drug for cancer.
Key words: 2-Methoxyestradiol, angiogenesis, morphometric analysis, mouse tumour model, chromosomal aberrations